| Literature DB >> 30448912 |
Martina Mandarano1, Guido Bellezza2, Maria Laura Belladonna3, Benoit J Van den Eynde4, Rita Chiari5, Jacopo Vannucci6, Giada Mondanelli3, Vienna Ludovini5, Ivana Ferri2, Fortunato Bianconi7, Rachele Del Sordo2, Lucio Cagini6, Elisa Albini3, Giulio Metro5, Francesco Puma6, Angelo Sidoni2.
Abstract
Several cancers, especially non-small cell lung cancer (NSCLC), are able to escape the immunosurveillance of tumor-infiltrating lymphocytes (TILs); among the molecules involved, the indoleamine 2,3-dioxygenase 1 (IDO-1) and the programmed cell death ligand-1 (PD-L1) play a crucial role. These aspects are of great interest in the current immunotherapeutic era, therefore the current study analyses the TILs, IDO-1, and PD-L1 interactions and their correlations with clinicopathological parameters and prognosis in NSCLC. One hundred ninety-three NSCLC surgical specimens, formalin-fixed, and paraffin-embedded were assessed for TILs density, TILs localization, IDO-1 (clone 4.16H1), and PD-L1 (clone E1L3N) immunohistochemical expressions. This data was correlated with clinicopathological parameters, disease free, and overall survivals. IDO-1 and PD-L1 high expressions were related to the solid pattern of adenocarcinomas (respectively p = 0.036 and p = 0.026); high PD-L1 expression was correlated with squamous histotype (p = 0.048). IDO-1 overexpression correlated with former smokers (p = 0.041), higher adenocarcinoma stages (p = 0.039), and with both higher TILs density and PD-L1 expression (respectively p = 0.025 and p = 0.0003). A better prognosis was associated with TILs intratumoral or mixed localizations (p = 0.029). TILs localization affects NSCLC prognosis; the higher expression of IDO-1 and PD-L1 in poorly differentiated and more aggressive lung adenocarcinomas, as well as the correlation between high PD-L1 expression and squamous cell histotype, confirm the more efficient immunoescaping of these NSCLC subgroups.Entities:
Keywords: IDO-1; Immunotherapy; Non-small cell lung cancer; PD-L1; Tumor-infiltrating lymphocytes
Mesh:
Substances:
Year: 2018 PMID: 30448912 DOI: 10.1007/s00428-018-2483-1
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.064